The efficacy of low-grade glioma chemotherapy was evaluated with 18F-FET-PET

In low-grade gliomas, the remission rate shown by imaging was relatively low, even if the patient's clinical performance or epilepsy improvedSimilar conditions exist in PATIENTS WITH WHO-III-GRADE GLIOMAS WHO ARE NOT OBVIOUS FOR ENHANCED MRI IMAGING ENHANCEMENT- Excerpted from the article(Ref: Suchorska B, et alJ Neurooncol2018 Sep;139 (3): 721-730doi: 10.1007/s11060-018-2919-0Epub 2018 Jun 8At present, for low-grade glioma, there is no uniform evaluation standard for chemotherapy effectResearch by Bogdana Suchorska of Neurosurgery at the University Hospital of Munich, Germany, found that 18F-FET-PET could be used as a method for evaluating the efficacy of chemotherapy in patients with MRI-enhanced imaging of non-enhanced gliomas, and the results were published in journal Of Neuro-Oncology in September 2018the study treated 61 patients with WHO-II or III gliomas with less obvious enhancement of MRI imaging, including temolamine, CCNU, or methylpyrifosPatients were examined for MRI and 18F-FET-PET before chemotherapy and after 6 courses of chemotherapyUsing the MRI-T2 sequence to calculate tumor volume, the biological tumor volume (BTV) and the maximum tumor diameter to brain ratio (maximal tumor-to-brain, TBRmax) were used to calculate the tumor volume using the TIME-activity curve (time-activity-curves, TAC)MRI evaluation efficacy indicators refer to raNO standards18F-FET-PET evaluation efficacy indicators are considered to be stable by reference to the following criteria: BTV decrease of 25% or TBRmax by 10% (responsive disease, RD);results showed that effective patients evaluated on 18F-FET-PET had the longest duration of treatment failure (time-to-treatment failure, TTF), TTF for RD was 78.5 months, SD was 24.6 months, and PD was 24.1 months (p-0.001)Multi-factor analysis also confirms this conclusion Similarly, the survival rate (post-chemotherapy survival, PCS) of effective patients assessed by 18F-FET-PET has a statistical advantage (p 0.001) The efficacy assessment based on MRI-T2 sequence imaging was not correlated with the prognosis of the patient The results also showed that both MRI and 18F-FET-PET test results found that the effect of chemotherapy was significantly related to epilepsy control, while dynamic PET efficacy evaluation was not related to prognosis In low-grade gliomas, the remission rate shown by imaging was relatively low, even if the patient's clinical performance or epilepsy improved Similar conditions exist in PATIENTS WITH WHO-III-GRADE GLIOMAS WHO ARE NOT OBVIOUS FOR ENHANCED MRI IMAGING ENHANCEMENT At present, the RANO standard is a common indicator of imaging to evaluate the prognosis of glioma, and the study found that there were significant differences in the evaluation of efficacy between 18F-FET-PET and MRI in the calculation of patient TTF Eight patients evaluated as SD according to MRI criteria were classified as PD according to the 18F-FET-PET evaluation criteria Therefore, the study revealed the value of 18F-FET-PET used to detect tumor prognosis , the 18F-FET-PET evaluation standard was significantly correlated with the prognosis of patients with low-grade gliomas, and showed that it was significantly better than the evaluation of MRI-T2 sequence imaging 18F-FET-PET enhances the chemical efficacy of patients with gliomas with out-of-tension of MRI imaging in early response, helping to adjust treatment strategies in a timely manner during treatment.